Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1653767 | 0.79 | ALDH1A1 (0.40) | HPGDTSHRALDH1A1 | |
| SCHEMBL16862855 | 0.79 | NPC1 (0.33) | NPC1RAB9AKMT2AHPGDTSHR | |
| SCHEMBL539282 | 0.79 | POLB (0.35) | HPGDTSHRALDH1A1KDM4E | |
| SCHEMBL3391334 | 0.79 | POLB (0.35) | HPGDTSHRALDH1A1KDM4E | |
| SCHEMBL19305204 | 0.79 | NPC1 (0.33) | NPC1RAB9AKMT2AHPGDTSHR | |
| Hydrochloric Acid SCHEMBL4632584 | 0.78 | NPC1 (0.32) | NPC1RAB9AKMT2AHPGDTSHR | |
| Hydrochloric Acid SCHEMBL995989 | 0.78 | NPC1 (0.32) | NPC1RAB9AKMT2AHPGDTSHR | |
| SCHEMBL27768847 | 0.73 | HSP90AA1 (0.38) | RAB9AKDM4E | |
| SCHEMBL28524419 | 0.72 | ALDH1A1 (0.37) | NPC1RAB9AKMT2AHPGDALDH1A1 | |
| SCHEMBL28528984 | 0.72 | ALDH1A1 (0.37) | NPC1RAB9AKMT2AHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233768-B1 | 1,3-BUTADIENE SYNTHESIS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-02-20 | — | — | EP | claimed |
| EP-3034486-A1 | 1,3-butadiene synthesis | LANXESS Deutschland GmbH (DE) | 2016-06-22 | — | — | EP | claimed |
| CN-117916227-A | Process for preparing perfuming intermediates | 弗门尼舍有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-115003649-A | Process for the preparation of perfuming intermediates | 弗门尼舍有限公司 | 2022-09-02 | — | — | CN | disclosed |
| EP-3233768-B1 | 1,3-BUTADIENE SYNTHESIS | ARLANXEO DEUTSCHLAND GMBH (DE) | 2019-02-20 | — | — | EP | disclosed |
| US-9856265-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2018-01-02 | — | — | US | disclosed |
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-10 | — | — | US | disclosed |
| US-9623022-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2017-04-18 | — | — | US | disclosed |
| US-9427440-B2 | Macrocyclic indole derivatives useful as hepatitis C virus inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-30 | — | — | US | disclosed |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen Sciences Ireland Unlimited Company (IE) | 2016-08-18 | — | — | US | disclosed |
| EP-3034486-A1 | 1,3-butadiene synthesis | LANXESS Deutschland GmbH (DE) | 2016-06-22 | — | — | EP | disclosed |
| EP-1912996-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1912997-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1913014-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007014925-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014920-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014918-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014923-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014922-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007014921-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226111-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | NPC1 514/4885RAB9A 2446/4885KMT2A 3645/4885 |
| US-20160235737-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CYP2A7, CYP3A7, HCCS | NPC1 514/4885RAB9A 2446/4885KMT2A 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.